Author:
Zeng Hai,Luo Meng,Li Zunjiang,Wen Junru,He Guoxin,Jin Yuelin,Fu Wenbin,Zhou Peng
Abstract
IntroductionHigh body mass index (BMI) is associated with risk of diabetes. Lorcaserin is a selective 5-hydroxytryptamine 2C agonist which exerts robust benefits on long-term weight loss by suppressing appetite among adults with overweight or obesity. The magnitude of efficacy of lorcaserin for preventing and remitting type 2 diabetes mellitus (T2DM) among those people remains undefined. Therefore, we plan to conduct this systematic review and meta-analysis to aggregate data from all published studies with regard to the issue to acquire reliable evidence.Methods and analysisWe will search various databases for relevant trials published up to June 2019. Randomised controlled trials investigating the efficacy of lorcaserin for preventing and remitting T2DM among overweight and obese population will be included. A standardised data form will be used to complete data search and extraction in duplicate. All discrepancies will be resolved by consensus. The primary outcome will be incidence of T2DM in patients with pre-diabetes. Secondary outcomes will include achievement of normoglycaemia in people with pre-diabetes, remission of hyperglycaemia in patients with diabetes, the proportion of patients with weight loss of at least 5% or 10% and hypoglycaemia incident. Data synthesis and statistical analysis will be performed for each outcome with Stata V.14.0.Ethics and disseminationEthics approval is not required. Results of our study will be submitted to a peer-review journal.PROSPERO registration numberCRD42019119136.
Funder
Guangdong Provincial Hospital of Chinese Medicine
Shanghai University of Medicine & Health Sciences
Reference43 articles.
1. WHO. Obesity and overweight fact sheet. Geneva: World Health Organization, 2016.
2. The Science of Obesity Management: An Endocrine Society Scientific Statement;Bray;Endocr Rev,2018
3. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants
4. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
5. Centers for Disease Control and Prevention. National Diabetes Statistics Report Estimates of Diabetes and Its Burden in the United States. Atlanta, GA: US Department of Health and Human Services, 2014.